Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 25, 2025Frontiers in ImmunologyOpen Access

Integrative profiling of lung cancer biomarkers EGFR, ALK, KRAS, and PD-1 with emphasis on nanomaterials-assisted immunomodulation and targeted therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

PLPeng LiHLHongmei LiWYWenqing Yan

Discussion

Loading...

Member takes

Overview

Analysis shows enhanced therapeutic potential of lung cancer biomarkers egfr, alk, kras, and pd-1, highlighting nanomaterials' role in immunomodulation.

Key Points

  • Models of key lung cancer biomarkers were developed, confirming their potential in targeted therapy.
  • Transcriptomic validation revealed significant overexpression of egfr (2.8-fold) and kras (2.3-fold) in lung cancer tissues, indicating clinical relevance.
  • Protein–protein interaction networks illustrated crucial links between egfr, alk, kras, and immune pathways essential for targeted interventions.
  • Nanomaterials are highlighted as promising carriers to improve drug delivery and enhance immune responses in lung cancer therapy.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/68af7b1f7567bf4f94ff2da3https://doi.org/10.3389/fimmu.2025.1649445
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Evaluation of PD-L1 Expression and Anti-EGFR Therapy in EGFR-Mutant Non-Small-Cell Lung Cancer2025
  2. 2Lung Cancer in the Era of Precision Oncology2025
  3. 3From missed mutations to liquid clues: a new era of EGFR diagnostics in NSCLC2025
  4. 4Molecular advances in early-stage and locally advanced non-small cell lung carcinoma: Shaping the future of precision oncology-systematic review2025
  5. 5CRISPR-BASED APPROACHES FOR THE DETECTION AND TARGETING OF LUNG CANCER BIOMARKERS: A NEW ERA IN PRECISION ONCOLOGY2025